To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. – 1
Overview
To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.
Full Title of Study: “Safety and Tolerability Study of Sublingual Lobeline”
Study Type
- Study Type: Interventional
- Study Design
- Primary Purpose: Diagnostic
Detailed Description
The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.
Interventions
- Drug: Lobeline
Clinical Trial Outcome Measures
Primary Measures
- Safety
Participating in This Clinical Trial
Inclusion Criteria
- Healthy individuals with a body mass index between 18 and 30. – Willing and able to give written consent. – Must have a negative drug test – Females must have a negative pregnancy test prior to study drug administration – Must have no medical contraindications as determined by routine testing Exclusion Criteria:
- Please contact the site for more information
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Overall Official(s)
- Reese Jones, M.D., Principal Investigator, Langley Porter Psychiatric Institute
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.